Genesys Capital:

Life science venture capital

We invest in early stage life science companies that are poised to change lives for the better.

About Genesys

Expertise. Experience. Insight.

Genesys Snapshot:

  • $300M+ Raised
  • $250M+ Invested
  • 5 Funds
  • 38 Companies
  • 18 Exits

Genesys Capital invests in and builds companies in the high-growth sectors of biotechnology, pharmaceuticals and medical technology. We have a proven track record of identifying emerging bioscience opportunities, and transforming them into commercially successful companies. That track record is fuelled by robust industry relationships, broad business expertise, and a deep understanding of the life sciences sector.

Genesys has generated more than 18 exits from 38 portfolio companies and has invested more than $250M. Our third institutional fund is closed and we’re actively considering new, high-potential life science companies for investment.

Why Genesys succeeds

Robust industry relationships, deep subject area knowledge, and proven insights let us identify viable companies early… and arm them to perform.

Stable and proven team

Our team has worked together for two decades of successful and continuous partnership.

Robust industry relationships

Long standing relationships with leading North American research institutes and universities provide us with early insights into top-tier research discoveries and world-class innovation, as well as preferential access to high potential deal flow and deep diligence expertise.

Proven strategy and profitable returns

We use our local world class research corridor as a lens to identify the most promising investment opportunities and apply our company creation strategy – a formula that has repeatedly proven its effectiveness with profitable returns.

Essential expertise for scale

We provide the critical expertise portfolio companies need to scale from great science on the bench to viable commercial enterprises competing in the global market. From thought leaders to executives to key advisors, our network and inhouse expertise give our companies the tools they need to perform.

Our Team

Expertise. Experience. Insight.

Deep subject knowledge, Robust industry relationships, Proven insight — meet the Genesys team.

The Genesys Team

Our team provides the deep domain expertise and experience needed to scale emerging opportunities in the lab into successful companies that will change the lives of countless patients around the world.

  • Jennifer Williams

    Jennifer Williams

    Chief Financial Officer

  • Damian Lamb

    Damian Lamb

    Co-founder, Managing Director

  • Lisa Low

    Lisa Low

    Senior Vice President, Finance

  • Kelly Holman

    Kelly Holman

    Co-founder, Managing Director

  • Sarah Farr

    Sarah Farr

    Senior Associate

  • Jamie Stiff

    Jamie Stiff

    Managing Director

  • Paras Sharma

    Paras Sharma

    Senior Associate

  • Genesys Capital

Our Portfolio

$250M invested
38 Companies
18 Exits

Our track record is a direct result of our approach to investment and company building.

Flosonics Medical secures $20M USD to accelerate growth in Series C funding led by New Leaf Venture Partners

SUDBURY, ON, Mar 19, 2024 — Flosonics Medical, a leader in wearable medical ultrasound has announced Series C financing of $20 million USD. The round was led by New Leaf Venture Partners, with participation from previous investors Arboretum Ventures, Genesys Capital, and iGan Partners. This new funding will support Flosonics as the company continues to innovate and drive market adoption of FloPatch, a first-in-class wearable Doppler ultrasound for hemodynamic assessments.

Fusion Pharmaceuticals to be acquired by AstraZeneca, accelerating development of next-generation radioconjugates to treat cancer

HAMILTON, ON and BOSTON, USA, March 19, 2024 -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.

Profound Medical in collaboration with Siemens Healthineers to further expand physician and patient access to TULSA procedure

TORONTO, Feb 27, 2024 — Profound Medical Corp, a commercial-stage medical device company that develops and markets customizable, incision-free therapies for ablation of diseased tissue, has announced it has entered into a non-exclusive collaboration with Siemens Healthineers, a global leader in medical technology. The collaboration aims to lay the groundwork for Profound to market a complete therapeutics solution, combining its TULSA-PRO® system with the MAGNETOM Free.Max magnetic resonance (“MR”) scanner from Siemens Healthineers, via Profound’s own sales force.

Fusion Pharmaceuticals enters exclusive worldwide license agreement with Heidelberg University and Euratom for actinium-based PSMA targeted radiotherapy

HAMILTON and BOSTON, Feb 16, 2024 — Fusion Pharmaceuticals Inc., a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced it has entered an exclusive worldwide license agreement with Heidelberg University and Euratom represented by the European Commission, Joint Research Centre (together, the "Licensors"). The license agreement grants Fusion exclusive worldwide rights to utilize, develop, manufacture and commercialize compounds covered by the patent, which includes 225Ac-PSMA I&T ("FPI-2265") for the treatment of prostate specific membrane antigen (PSMA)-expressing cancers.

Inversago clinical trial updates on Phase 2 INV-202 and Phase 1 INV-347

MONTREAL, Jan 2024 — CLINICAL TRIAL UPDATES ON INV-202 and INV-347 — Novo Nordisk has initiated a phase 1 trial with a next-generation oral small molecule CB1 receptor blocker INV-347, investigating its safety, tolerability and pharmacokinetics. In the second half of 2023, Novo Nordisk also initiated a phase 2 trial in people with obesity with INV-202. INV-202 is also an oral small molecule CB1 receptor blocker, and is currently in phase 2 for diabetic kidney disease. Both INV-202 trials are expected to complete in the second half of 2025. All trials are conducted by Inversago Pharma, which was acquired by Novo Nordisk in 2023.

Fusion Pharmaceuticals clinical program and manufacturing updates – FPI-2265 and FPI-1434

HAMILTON and BOSTON, Jan 4, 2024 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced significant progress with its FPI-2265 development program, an update on FPI-1434 Phase 1 Cohort 2 data, and the production of the first clinical doses at the Company's proprietary manufacturing facility.

Fusion Pharmaceuticals strengthens actinium supply with onsite isotope production through expanded BWXT medical collaboration

HAMILTON and BOSTON, Nov 16, 2023 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc. (NYSE: BWXT), announced that the companies have entered into a new agreement for supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

Fusion Pharmaceuticals appoints life science industry leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors

HAMILTON and BOSTON, Oct 16, 2023 — Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company developing next-generation radiopharmaceuticals as precision medicines, announced the appointment of Jeremy Bender, Ph.D., M.B.A., Teresa Bitetti, M.B.A., and David Meek to its Board of Directors, effective today.

For older news items, visit the Genesys News Archive here

Contact us

We’re listening!

Genesys Capital is located at Front St and University Ave in downtown Toronto, in the heart of the life science hub.